Literature DB >> 19072347

Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.

Henning Grønbaek1, Karen Louise Thomsen, Jørgen Rungby, Ole Schmitz, Hendrik Vilstrup.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common disease that is usually accompanied by insulin resistance (IR). Whether or how NAFLD and IR are temporally and mechanistically related is controversial. Recent studies focus on their epidemiology, the importance of dietary fat, the role of adipocytokines and the sterol regulatory element-binding protein-1c. NAFLD and IR may progress to severe diseases, such as cirrhosis, diabetes or both, and understanding the pathogenesis of the precursor conditions has preventive and therapeutic implications. This review focuses on the possible relationships between NAFLD and IR and the treatment options available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19072347     DOI: 10.1586/17474124.2.5.705

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  9 in total

Review 1.  Exposure to ambient air particulate matter and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Domenico Capone; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

2.  Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study.

Authors:  Beverley Balkau; Celine Lange; Sylviane Vol; Frederic Fumeron; Fabrice Bonnet
Journal:  BMC Gastroenterol       Date:  2010-06-07       Impact factor: 3.067

3.  Choline supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferase-deficient mice via increased glucagon action.

Authors:  Gengshu Wu; Liyan Zhang; Tete Li; Azeret Zuniga; Gary D Lopaschuk; Liang Li; René L Jacobs; Dennis E Vance
Journal:  J Biol Chem       Date:  2012-11-25       Impact factor: 5.157

4.  Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A L C Schneider; M Lazo; C E Ndumele; J S Pankow; J Coresh; J M Clark; E Selvin
Journal:  Diabet Med       Date:  2013-04-12       Impact factor: 4.359

5.  Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Authors:  Ornella de Bari; Brent A Neuschwander-Tetri; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  J Lipids       Date:  2011-11-03

Review 6.  Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets.

Authors:  Ya-Hui Ding; Yuan Ma; Lin-Yan Qian; Qiang Xu; Li-Hong Wang; Dong-Sheng Huang; Hai Zou
Journal:  Oncotarget       Date:  2017-07-24

Review 7.  History of Nonalcoholic Fatty Liver Disease.

Authors:  Amedeo Lonardo; Simona Leoni; Khalid A Alswat; Yasser Fouad
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

Review 8.  Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.

Authors:  Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

9.  Alanine aminotransferase is associated with an adverse nocturnal blood glucose profile in individuals with normal glucose regulation.

Authors:  Jian Zhou; Yifei Mo; Hong Li; Xingwu Ran; Wenying Yang; Qiang Li; Yongde Peng; Yanbing Li; Xin Gao; Xiaojun Luan; Weiqing Wang; Weiping Jia
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.